A major challenge in metastatic colorectal cancer (mCRC) is the identification of specific biomarkers that are likely to predict which patients will benefit from a specific treatment. To this date, a number of studies have shown that a tumour's mutational profile influences treatment outcome in patients with mCRC and should, therefore, be used to guide treatment decision. For more than 5 years now, we know that patients with tumours harbouring mutations in exon 2, codons 12 and 13 of the KRAS oncogene gain no benefit from the administration of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs), Cetuximab and Panitumumab. It has just recently being elucidated that KRAS mutations outside codons 12 and 13 and mutations in the NRAS gene confer resistance to Cetuximab and Panitumumab, as well. Thus, since June 2013, the analysis of exons 2, 3 and 4 of KRAS and NRAS has been incorporated in daily clinical practice to improve patients' selection for anti-EGFR moAbs treatment. Nevertheless, even if patients' outcome under anti-EGFR moAbs therapy is improved with better selection based on Ras mutational status, more research is needed in this field; the matter is far from being resolved, since there are still a minority of wt RAS patients who do not respond upfront to such a treatment.
exon 2, codons 12 and 13 of the KRAS oncogene gain no benefit from anti-epidermal growth factor receptor (EGFR) treatment, specifically from the two monoclonal antibodies (moAbs) against EGFR, Cetuximab and Panitumumab. [2, 3] and that eventually a detrimental effect in Kras mutant occurred when Oxaliplatin was part of the chemotherapy backbone. Nevertheless, it soon became evident that this approach was not enough to explain the full picture, since several patients with KRAS wild-type (wt) tumours did not respond to anti-EGFR inhibition.
[2] Beyond KRAS exon 2 mutations, the clinical relevance of other proposed mechanism of resistance to anti-EGFR moAbs, such as KRAS mutations outside codons 12 and 13, and mutations in other RAS family members, such as NRAS, is just recently being elucidated, with the aim to better select patients who have the highest probability to respond to this kind of treatment. [4, 5] 
KRAS mutations in exon 2 andcodons 12 and 13
Although the anti-EGFR moAbs Cetuximab and Panitumumab were initially registered for patients whose tumours were found to immunohistochemically express the EGFR protein, it soon became clear that this methodology was neither enough nor adequate to predict treatment efficacy. The KRAS proto-oncogene encodes K-ras, a G protein that has a key role in the Ras/ MAPK signalling pathway. K-ras is located downstream of many growth factor receptors, including EGFR, that are involved in CRC carcinogenesis. The activation of a growth factor receptor induces the recruitment of K-ras, which initiates the activation of a cascade of serinethreonine kinases leading to the signal transduction from the cell surface to the nucleus.[6] KRAS mutations are present in more than one-third of CRCs and in approximately 90% of the cases they are located in exon 2 and codons 12 and 13.[2,3] KRAS mutations lead to the activation of one of the most important pathways for cell proliferation, the Ras/MAPK pathway, by inducing cyclin D1 synthesis. Consequently, in the presence of a KRAS mutation this pathway activation cannot be significantly inhibited by an anti-EGFR moAb (Cetuximab or Panitumumab), which acts upstream the K-ras protein. [7] In a number of trials and studies, it has been shown that specific KRAS mutations in the hotspots of codons 12 and 13 were predictors of resistance to anti-EGFR moAbs therapy and were associated with reduced efficacy and shorter progression-free survival (PFS) and overall survival (OS). [2, 3, [8] [9] [10] [11] Thus, in June 2009, mutational analysis of KRAS codons 12 and 13 in the tumours of CRC patients became mandatory at the presentation of metastatic disease before the administration of anti-EGFR moAbs.
Despite that, as previously already noted, not all patients with KRAS tumours benefit from the administration of Cetuximab or Panitumumab. In fact, the response rate of anti-EGFR moAbs is less than 25% when they are administered as salvage monotherapy, clearly indicating that other mechanism of resistance must be implicated in this process. [12] [13] [14] [15] 
KRAS mutations outside hotspots in codons 12 and 13
Besides the majority of KRAS mutations that are located in exon 2 (codons 12 and 13), others exist, accounting approximately for 10% of the KRAS mutated cases and found mainly in exon 3 (codon 61) and 4 (codons 117 and 146). [4, 5, 16] Preclinical data indicate that the above-mentioned mutations behave similar to the hotspots codon 12 and 13 mutations, leading to RAS-RAF-MAPK kinase pathway activation. In contrast, other KRAS mutations such as those found in codons 19 and 164 are phenotypically equivalent to wt KRAS. [17, 18] The clinical relevance of codons 61 and 146 KRAS mutations has been retrospectively investigated in small patients' cohorts and lack of response to anti-EGFR moAbs treatment has been documented. [16, 17] In addition, in the retrospective analysis of the Panitumumab registration trial, it was shown that the addition of codon 61 KRAS mutation alongside the already established ones slightly improved patients' selection for anti-EGFR moAbs treatment administration.
[5] Furthermore, in the large PRIME study, [4] as well as in PEAK [19] when patients were considered as RAS wt if their tumours were wt for KRAS codons, 12, 13, 61 and 146 (thus, exons 2, 3 and 4), a significant improvement in response rate, PFS and OS was documented. In line with this mounting evidence and in accordance with the strong biologic rational, from June 2013, the analysis of exons 2, 3 and 4 of KRAS and their wt characterization is now mandatory before the administration of anti-EGFR moAbs treatment in daily clinical practice.
NRAS mutation status
NRAS encodes for a protein -a member of the RAS superfamily of GTPases, and like the rest of them, plays a key role in the critical MAPK signalling pathway. Besides CRC, NRAS mutations are found in other solid tumours as well, like melanomas and thyroid carcinomas. [20, 21] Approximately 80% of the reported NRAS gene mutations are located in codon 61.
[20] NRAS mutation status has been shown to putative predict response to BRAF inhibition in metastatic melanoma patients [22, 23] and anti-EGFR treatment in mCRC. [5] Retrospectively, it was shown that patients with KRAS and BRAF wt but NRAS mutated tumours had significantly reduced response rates when treated with Cetuximab in the salvage treatment setting.
[18] Furthermore, in the retrospective analysis of the Panitumumab registration trial, it was shown that Panitumumab had no effect in KRAS wt but in NRAS mutated patients.
[5] As already previously mentioned for KRAS mutational analysis of exons 3 and 4 besides exon 2, in the large PRIME study, [4] as well as in PEAK [19] when patients were considered as RAS wt if their tumours were wt for KRAS codons, 12, 13, 61 and 146 (thus, exons 2, 3 and 4) and NRAS exons 2 (codons 12 and 13), 3 (codon 61) and 4 (codons 117 and 146), a significant improvement in response rate, PFS and OS was documented. In line with this mounting evidence and in accordance with the strong biologic rational, from June 2013, the analysis of exons 2, 3 and 4 of NRAS is also incorporated in daily clinical practice in the pre-treatment analytical panel, in addition to KRAS, to improve patients' selection who are candidates for anti-EGFR moAbs treatment.
The better selection of the target patient population increases the benefit/risk ratio of the use of anti-EGFR MoAbs in all lines. Depending on the technics used to extend the mutation analysis, the percentage of patients with Wild-type Kras Exon 2 harbouring less frequent mutations in other codons or exons in K and N ras varies between 15% and 25%. The population enrichment based on Kras was demonstrated mostly on retrospective or prospective/retrospective analysis, starting from no Kras testing, followed by Kras Exon 2 testing and more recently Kras and Nras exons 2, 3 and 4 tasting chronologically over a period of 10 years or more.
Application and future considerations
Important technical application considerations regarding all the above-mentioned mutational analysis are the validation of the assay for testing KRAS/NRAS mutation in exons 2 (codons 12, 13) -3 (codon 61) -4 (codons 117 and 146), the evaluation of the sensitivity of the methodology for each exon, the comparison of sensitivity and specificity of the methodology when surgical or biopsy specimens are analysed and the development of a multiplex assay (compared with the standard techniques). Furthermore, hugely important aspects are the correlations of clinical and pathological parameters to the specific KRAS and NRAS mutations in mCRC patients, as well as the willingness of the clinicians, the medical oncologists, to assess all KRAS/ NRAS mutations in exons 2 (codons 12 and 13), 3 (codon 61) and 4 (codons 117 and 146) in the tumours of their mCRC patients to choose the best possible treatment algorithm.
Even if outcomes in terms of response rate, PFS and OS are improved with better selection on the Ras mutational status, there are still a minority of patients not responding upfront to combined modality treatments with anti-EGFR MoAbs. Further research should be performed to look at other pre-existing mechanisms of resistance. Finally, most patients under treatment will also develop tumour progression reflecting the possibility of tumour escape and acquisition of resistance under therapeutic pressure that will need to be better understood to be appropriately treated. 
